Gemina is a clinical-stage bio-sensing company focuses on the development of fast, affordable and accurate diagnostics that are designed to offer clinical-grade testing at home or at work.

Gemina is founded on transformative bio-chemistry developed by Robert Greene and was spun-out from Ecomine Technologies in 2020. Dual-affinity biomolecules have been shown to be effective in detecting COVID-19 antigens and may have wide applications in the detection of respiratory, infectious and sexually-transmitted diseases.

Investment opportunity

• Differentiated accuracy and limit of detection profile to address limitations of rapid testing
• Gemina is enabling both quantitative testing (how much), and multi-target testing (multiple diseases)

Unmet need:

• A “universal binding” platform to bring accurate, rapid point of care testing into the next generation of diagnosis and wellbeing monitoring

Market opportunity:

• In-Vitro Diagnostics for Human Health ($83B)
• At home testing segment ($8B by 2027)
• Point of care segment ($11B) (>$100B)
• Agrochemicals ($55B)

Key risks:

• Highly competitive environment chain
• Complex manufacturing and supply
• Differentiated product requirement